Abstract
BackgroundIn ORAL Surveillance, a post-approval safety study conducted in RA patients aged ≥50 years with ≥1 cardiovascular (CV) risk factor, non-inferiority was not shown for MACE and malignancy (excluding nonmelanoma...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have